2022年英国风湿病学会《孕期和哺乳期用药-免疫调节抗风湿药物和皮质激素类药物》指南解读
Understanding of"Prescribing drugs in pregnancy and breastfeeding:immunomodulatory anti-rheumatic drugs and corticosteroids"guideline by the British Society of Rheumatology in 2022
姚蓉 1董晓静1
作者信息
- 1. 重庆医科大学附属第二医院妇产科,重庆 400010
- 折叠
摘要
2022年11月2日英国风湿病学会(BSR)发布了《孕期和哺乳期用药-免疫调节抗风湿药物和皮质激素类药物》指南,该指南针对孕期和哺乳期处方抗风湿药物提供指导建议,内容包括抗疟药、糖皮质激素、传统合成的抗风湿药物(csDMARDs)和免疫制剂、生物制剂(bDMARDs)和靶向制剂(tsDMARDs)在妊娠期、哺乳期的安全性及对父亲用药的建议,补充了 bDMARDs和tsDMARDs的推荐意见,旨在为医务人员使用该类药物提供依据.
Abstract
The British Society for Rheumatology(BSR)published"Prescribing drugs in pregnancy and breastfeeding:immunomodulatory anti-rheumatic drugs and corticosteroids"guideline on November 2,2022,the guideline provides the guidance suggestion on prescribing antirheumatic drugs during pregnant period and lactation period,the contents include the safety of antimalarials;corticosteroids;conventional synthetic DMARDs(csDMARDs)and immunosuppressive therapies;biologic DMARDs(bDMARDs);and targeted syn-thetic DMARDs(tsDMARDs)during pregnant period and lactation period,the recommendations for father medication,and replenish the recommendations for bMDARDs and tsDMARDs in order to provide a basis for the medical staff to use these kinds of drugs.
关键词
风湿免疫病/妊娠期/哺乳期/父亲/药物/安全性Key words
Rheumatic immune/Pregnancy/Breastfeeding/Father/Drugs/Safety引用本文复制引用
基金项目
国家儿童健康与疾病临床医学研究中心临床医学研究一般项目(NCRCCHD-2020-GP-16)
出版年
2024
国家科技期刊平台
NSTL
万方数据